期刊文献+

基于叶酸受体靶向的肿瘤诊断和治疗策略 被引量:1

Tumor diagnosis and treatment strategies based on targeting folate receptor
原文传递
导出
摘要 叶酸受体(folate receptors,FRs)在人类多种癌症中过表达,如卵巢癌、肺癌、乳腺癌、脑癌等。而叶酸(folic acid,FA)是FRs的高亲和力配体,当与其他分子结合时,仍保留其受体结合特性。基于FRs的靶向技术已成功应用于叶酸受体阳性肿瘤的诊断和治疗中,且显著增强了对癌细胞的特异性和选择性。因此,基于FRs的靶向策略有望提高临床上相关抗癌药物的安全性和有效性。本文主要对基于FRs靶向的肿瘤诊断及治疗策略进行综述,特别关注这一领域的最新进展以及未来可能的发展方向。 Folate receptors(FRs)are overexpressed in a variety of human cancers,such as ovarian,lung,breast and brain cancers.Folic acid(FA)is a high⁃affinity ligand of FRs that retains the receptor⁃binding properties after binding to other molecules.FRs targeting technology has been successfully applied to the diagnosis and treatment of FRs⁃positive tumors,and has significantly enhanced the specificity and selectivity to cancer cells.Therefore,FRs targeting strategies are expected to improve the safety and efficacy of clinically relevant anti⁃cancer drugs.In this review,we mainly summarizes tumor diagnosis and treatment strategies based on folate receptors targeting,with special attention to the latest progress in this field and possible future development.
作者 何文丽 董星 闫梦 许佳祺 向柏 杨少坤 曹德英 HE Wen-li;DONG Xing;YAN Meng;XU Jia-qi;XIANG Bai;YANG Shao-kun;CAO De-ying(Hebei Medical University,Shijiazhuang 050000,China)
机构地区 河北医科大学
出处 《中国新药杂志》 CAS CSCD 北大核心 2023年第15期1531-1537,共7页 Chinese Journal of New Drugs
基金 国家自然科学基金资助项目(81973251) 河北省自然科学基金资助项目(H2019206445) 河北医科大学2022年大学生创新性实验计划资助项目(USIP2022276)。
关键词 叶酸受体 叶酸 肿瘤 诊断 治疗 folate receptors folic acid tumor diagnosis treatment
  • 相关文献

参考文献1

二级参考文献139

  • 1Ackery, D., Yardley, J., 1993. Raaionuclide-targeted therapy for the management of metastatic bone pain. Semin. Oncol., 20 (3 Suppl. 2):27-31.
  • 2Alberti, C., 2012. From molecular imaging in preclinical/ clinical ontology to theranostic applications in targeted tumor therapy. Eur. Rev. Med. Pharmacol. Sci., 16(14): 1925-1933.
  • 3Alcindor, T., Witzig, T.E., 2002. Radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for patients with relapsed CD20+ B-cell non-Hodgldn's lymphoma. Curr. Treat. Options Oncol., 3(4):275-282. [doi:10.1007/ s11864-002-0027-y].
  • 4Alonso-Ruiz, A., Perez-Ruiz, F., Calabozo, M., et al., 1998. Efficacy of radiosynovectomy of the knee in rheumatoid arthritis: evaluation with magnetic resonance imaging. Clin. Rheumatol., 17(4):277-281. [doi: 10.1007/BF01451005].
  • 5Anderson, P., Nunez, R., 2007. Samarium lexidronam (153Sm- EDTMP): skeletal radiation for osteoblastic bone metas- tases and osteosarcoma. Expert Rev. Anticancer Ther., 7(11):1517-1527. [doi:10.1586/14737140.7.11.1517].
  • 6Arslan, N., Emi, M., Alagoz, E., et al., 2011. Selective intraarterial radionuclide therapy with Yttrium-90 (Y-90) mierospheres for hepatic neuroendocrine metastases: initial experience at a single center. Vojnosanit. Pregl., 68(4):341-348. [doi: 10.2298/VSP1104341A].
  • 7Atkins, H.L., 1998. Overview of nuclides for bone pain palliation. Appl. Radiat. 1sot., 49(4):277-283. [doi:10. 1016/S0969-8043(97)00039-0].
  • 8Azinovic, I., DeNardo, G.L., Lambom, K.R., et al., 2006. Survival benefit associated with human anti-mouse antibody (HAMA) in patients with B-cell malignancies. Cancer Immunol. Immunother., 55(12):1451-1458. [doi: 10.1007/s00262-006-0148-4].
  • 9Bartolomei, M., Bodei, L., de Cicco, C., et al., 2009. Peptide receptor radionuclide therapy with 9y-DOTATOC in recurrent meningioma. Eur. J.. Nucl. Med. Mol. Imaging, 36(9):1407-1416. [doi: 10.1007/s00259-009-1115-z].
  • 10Baum, R.P., Kulkami, H.R., 2012. THERANOSTICS: from molecular imaging using Ga-68 labeled tracers and PET/CT to personalized radionuclide therapy-the bad Berka experience. Theranostics, 2(5):437-447. [doi:10. 7150/thno.3645].

共引文献6

同被引文献14

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部